Atrium Therapeutics: T. Rowe Price reports 3.7%
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atrium Therapeutics, Inc. (RNA) was the subject of an amended ownership report in which T. Rowe Price Associates, Inc. listed 640,034 common shares as beneficially owned as of September 30, 2026, equal to 3.7% of the class. It reported sole voting power over 639,822 shares and sole dispositive power over 640,034 shares, with no shared voting or dispositive power. T. Rowe Price Associates stated that the report is not an admission of beneficial ownership and expressly denied being the beneficial owner of the securities.
Key Figures
Key Terms
beneficially owned regulatory
Sole voting power regulatory
Sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.